Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Journal of the American Academy of Dermatology|January 25, 2002
Sweet's syndrome as initial presentation of diffuse large B-cell lymphomaJens Gille, Konstanze Spieth, Roland KaufmannJournal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 16, 2005
Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancerJens Gille, Konstanze Spieth, Roland KaufmannCancer Chemotherapy and Pharmacology|July 25, 2003
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot studyKonstanze Spieth, Roland Kaufmann, Jens GilleDermatology (Basel, Switzerland)|October 26, 2002
Mycosis-fungoides-type cutaneous T cell lymphoma of the hands and soles: a variant causing delay in diagnosis and adequate treatment of patients with palmoplantar eczemaKonstanze Spieth, Marcella Grundmann-Kollmann, Ulf Runne, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology GroupSelma Ugurel, Dirk Schadendorf, Claudia Pföhler, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trialSarah Heinze, Friederike Egberts, Susanne Rötzer, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2011
Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial)Susanne Ziefle, Friederike Egberts, Sarah Heinze, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology GroupRoland Kaufmann, Konstanze Spieth, Ulrike Leiter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.Pageof 1